Nouri M E
Clin Ther. 1984;6(2):142-50.
In a double-blind, parallel four-day trial with 51 patients, the anti-inflammatory, antiexudative, and antipyretic effects of nimesulide were compared with placebo in patients with acute inflammation of the upper respiratory tract. Patients who received nimesulide showed improvement in the signs and symptoms evaluated: pharyngeal redness, tonsillar redness, tonsillar swelling, hoarseness, sore throat, headache, and arthralgia. A statistically significant difference between nimesulide and placebo was evident for all parameters (P less than 0.01). The global use rating of the two drugs showed that nimesulide was useful in 22 (92%) of 24 patients and that placebo was useful in four (16%) of 25 patients (P less than 0.01). There were no side effects associated with nimesulide; one placebo-treated patient had diarrhea and withdrew from the study, and one nimesulide-treated patient withdrew for nonmedical reasons. No variations in laboratory tests were noted.
在一项针对51名患者的双盲、平行四日试验中，将尼美舒利在上呼吸道急性炎症患者中的抗炎、抗渗出和退热作用与安慰剂进行了比较。接受尼美舒利治疗的患者在评估的体征和症状方面有所改善：咽部发红、扁桃体发红、扁桃体肿大、声音嘶哑、喉咙痛、头痛和关节痛。尼美舒利与安慰剂在所有参数上均存在统计学显著差异（P<0.01）。两种药物的总体使用评分显示，24名患者中有22名（92%）认为尼美舒利有效，25名患者中有4名（16%）认为安慰剂有效（P<0.01）。尼美舒利未出现相关副作用；一名接受安慰剂治疗的患者出现腹泻并退出研究，一名接受尼美舒利治疗的患者因非医学原因退出。未观察到实验室检查结果有变化。
